CYP19A1 and breast carcinoma: In the present study, ~70% patients were postmenopausal; and according to the results of several clinical trials, postmenopausal advanced breast cancer patients are initially recommended to undergo endocrine therapy predominantly consisting of a nonsteroidal (letrozole or anastrozole) or steroidal (exemestane) aromatase inhibitor (28–30).